BOSTON, April 3, 2017 /PRNewswire/ -- BERG, a biopharmaceutical company uncovering health solutions through a data-driven,biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG's leading product candidate, BPM 31510, to augment immune responses and potentially improve outcomes of
"These insights into the mechanism of action of BPM 31510 provide further validation for its clinical potential to preferentially treat patients with highly metabolic tumors, like pancreatic cancer and GBM," said Niven R. Narain, co-founder, president and chief executive officer of BERG. "We are encouraged by the findings presented at AACR, especially in areas such as immuno-oncology, where novel methods to boost the immune system have the potential to significantly improve patient response and outcomes. In addition, our innovative platform's identification of novel biomarkers in the prostate has the potential to select patients that will mostly likely respond to treatment."
The seven abstract titles will be presented on the following dates and times:
Monday: April 3, 2017
Tuesday: April 4, 2017
Wednesday: April 5, 2017
At AACR (Booth 3424), BERG will be demonstrating the capabilities of the company's Interrogative Biology® platform. Its unbiased, algorithm-based approach guides the discovery, development and clinical evaluation of product candidates to create the next generation of drugs and diagnostics. BPM 31510 is one of the first cancer drug candidates guided in development by artificial intelligence. This product candidate may normalize cell metabolism by shifting the cells' energy utilization so they undergo natural cell death. Data from preclinical and human trials indicates that treatment with BPM 31510 as a single agent potentially leads to tumor regression, and that anti-tumor activity increases in combination with chemotherapy agents.
Full abstracts of the posters are available on the AACR website (www.aacr.org).
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process. BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology. Its platform has the potential to provide:
For additional information, please visit www.BERGhealth.com.
CONTACT: Lisa Rivero, Ogilvy, 617-761-6746
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/berg-announces-bpm-31510-data-presentations-at-2017-aacr-in-immuno-oncology-glioblastoma-mutiforme-pancreatic-cancers-and-novel-prostate-cancer-biomarker-panel-300433281.html
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All